Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 5:56 PM
Ignite Modification Date: 2025-12-24 @ 5:56 PM
NCT ID: NCT06435468
Eligibility Criteria: Inclusion Criteria: * Patients * minor or adult patient of any age with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (\<18 years), or syndromic or familial * relative of a minor or adult patient with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (\<18 years of age) or syndromic or familial, * weight greater than 5 kg * Patient/parents/guardians who were informed of the study and signed the consent form. * patient affiliated to a social security scheme Healthy volunteer participants * minor or adult participants with no age restrictions * weight over 5 kg * Subject /Parents/guardians who were informed of the study and signed a consent form. * Patient affiliated to a social security scheme Exclusion Criteria: Patients \- Subjects /Parents/guardians, refusing to participate in the study Healthy volunteer participants : * active infection (viral, bacterial, parasitic) * history of neoplasia (\< 5 years) or current neoplasia * participants with a personal or family history of autoimmune disease * immunocompromised participant (immune deficiency or transplant recipient) * Subjects/parents/guardians refusing to participate in the study * Adults under legal protection (guardianship, curatorship)
Healthy Volunteers: True
Sex: ALL
Minimum Age: 1 Year
Study: NCT06435468
Study Brief:
Protocol Section: NCT06435468